OR-CXL-CONSORTIUM
10.11.2020 15:02:13 CET | Business Wire | Press release
The CXL™ Consortium, an industry standards body dedicated to advancing Compute Express Link™ (CXL) technology, today announced the release of the CXL 2.0 specification. CXL is an open industry-standard interconnect offering coherency and memory semantics using high-bandwidth, low-latency connectivity between host processor and devices such as accelerators, memory buffers, and smart I/O devices. The CXL 2.0 specification adds support for switching for fan-out to connect to more devices; memory pooling for increased memory utilization efficiency and providing memory capacity on demand; and support for persistent memory – all while preserving industry investments by supporting full backwards compatibility with CXL 1.1 and 1.0.
“Datacenter architectures continue to evolve rapidly to support the growing demands of emerging workloads for Artificial Intelligence and Machine Learning, with CXL technology keeping pace to meet the performance and latency demands,” said Barry McAuliffe, president, CXL Consortium. “Designed with breakthrough performance and easy adoption as guiding principles, the CXL 2.0 specification is a significant achievement from our dedicated technical work group members.”
Key Highlights of the CXL 2.0 Specification:
- Adds support for switching to enable device fan-out, memory scaling, expansion and the migration of resources.
- Includes memory pooling support to maximize memory utilization, limiting or eliminating the need to overprovision memory.
- Introduces standardized fabric manager specification for inventory and resource allocation to enable easier adoption and management of CXL-based switch and fabric solutions.
- Provides standardized management of the persistent memory interface and enables simultaneous operation alongside DDR, freeing up DDR for other uses.
- Introduces managed hot-plug support to take a CXL device online or offline from the system.
- Adds link-level Integrity and Data Encryption (CXL IDE) to provide confidentiality, integrity and replay protection for data transiting the CXL link.
- Supports a wide variety of industry interconnect form factors and standardized management interfaces to ease implementation.
- Includes Compliance and Interoperability specifications and in-system testing to enable a robust and interoperable multi-vendor ecosystem.
“The CXL Consortium has moved with breathtaking speed to deliver its second generation CXL 2.0 spec, even before products incorporating the first generation CXL 1.0 and 1.1 specs have reached the market,” observed Nathan Brookwood, Research Fellow at Insight 64. “The new 2.0 features, including switching, memory pooling and persistent memory support pave the way for fully disaggregated systems in which pools of accelerators, DRAM and persistent memory storage can be dynamically connected to any one of 16 host servers to meet application demands. These features will enable system designers to invent entirely new types of systems that architects could only dream about just a few years ago.”
The CXL 2.0 specification is available for public download at https://www.computeexpresslink.org/download-the-specification .
Additional Resources:
- White Paper: Introducing the CXL 2.0 Specification
- CXL Consortium Member Company Statements of Support
About the CXL™ Consortium
The CXL Consortium is an industry standards body dedicated to advancing Compute Express Link™ (CXL) technology. CXL is a high-speed interconnect offering coherency and memory semantics using high-bandwidth, low-latency connectivity between the host processor and devices such as accelerators, memory buffers, and smart I/O devices. For more information or to join, visit www.computeexpresslink.org .
Compute Express Link and CXL are trademarks of the CXL Consortium. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom